血清CD44及其拼接变异体sCD44v6测定对肺癌的诊治意义

Clinical significance of detecting serum CD44 in lung carcinoma

目的 :探讨测定血清中可溶性 CD44含量在肺癌中的临床意义。方法 :用酶联免疫吸附试验(EL ISA)检测 45例肺癌患者及 18例正常人血清中可溶性 CD44 s(s CD44 s)和可溶性 CD44 v6 (s CD44 v6 )的含量。结果 :化疗前肺鳞癌和腺癌患者血清 s CD44 s和 s CD44 v6水平明显高于小细胞肺癌 (SCL C)患者和正常组 ,差异非常显著 ;SCL C与正常人比较差异无显著性 ;非小细胞肺癌 (NSCL C) + 期患者血清s CD44 v6明显高于 + 期和正常对照组 (P<0 .0 0 1)。化疗后鳞癌患者血清 s CD44 s、s CD44 v6和腺癌患者血清 s CD44 v6均较化疗前明显下降 (分别为 P<0 .0 0 1,P<0 .0 5 ,P<0 .0 0 1)。结论 :血清 s CD44 s和 s CD44 v6水平可作为诊断 NSCL C及区分肺癌组织学类型的辅助指标 ;NSCL C患者的血清 s CD44 v6水平与其临床分期有关 ;动态检测二者的含量有助于 NSCL

Objective:To explore the clinical significance of detecting soluble serum CD44 in lung carcinomas.Methods:Levels of serum soluble CD44 standard(sCD44s) and CD44 variant 6(sCD44v6) in 45 patients with lung carcinoma and in 18 healthy individuals were measured by ELISA.Results:Before the initiation of chemotherapy, serum sCD44s and sCD44v6 in patients with squamous cell carcinoma(SCC) and with adenocarcinoma(ADC) were markedly higher than those in small cell lung carcinoma(SCLC) patients and in the controls. However,no difference was noted between SCLC and healthy individuals. The sCD44v6 serum concentration of patients in stage Ⅲ, Ⅳ non small cell lung carcinoma (NSCLC) was significantly higher than that of patients in stage Ⅰ, Ⅱ NSCLC and that of the control group(P<0.001) . Serum sCD44s and sCD44v6 levels became lower in SCC patients who achieved a complete chemotherapy course (P<0.001 and 0.05, respectively). Serum sCD44v6 levels in ADC patients decreased after therapy(P<0.001).Conclusion:Serum levels of CD44s and CD44v6 may be useful in diagnosis of NSCLC and differentiation of histiotypes of lung carcinoma. Serum level of CD44v6 was associated with the clinical stages in patients with NSCLC. Serum sCD44s and sCD44v6 were contributory to monitoring treatment response in patients with NSCLC.[FK(WB80011。6]